UBS sees upside for Thermo Fisher, Agilent


UBS lifts its price targets on Thermo Fisher (TMO +0.3%) and Agilent (A +0.5%) to $127 (from $107) and to $65 (from $57), respectively.

Analyst Daniel Arias likes the "financial merits of [the TMO] LIFE deal (est 20% accretion in 2014) and TMO's competitive position going forward." New target is 18X forward estimates.

As for A, the company "should benefit from the gradual macro improvement [while] enthusiasm for the spinoff of EMG appears high, as units comprising the new A performed well in Q4 and appear to be taking share."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs